Eisai plots label expansion for subcutaneous Leqembi, details early launch progress

Eisai said it’s planning a rolling FDA submission next month to expand the use of its Biogen-partnered subcutaneous Alzheimer’s treatment, the latest effort to stoke the companies’ rivalry with Eli Lilly.

Leqembi was first approved …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844